The new drug application is about to be submitted again! Obeticholic acid can finally eat the $40 billion cake of NASH? 2022-08-26
After the failure of several NASH drugs from Novartis, Boehringer Ingelheim, Genfit, Gilead, Albireo and NGM, the field of nonalcoholic steatohepatitis (NASH) finally ushered in positive progress. Intercept announced the latest data from the pivotal Phase 3 REGENERATE study of its representative dru
Read More